Abstract | BACKGROUND: METHODS: Archived human pancreatic cancer specimens were used to assess gene expression and microvessel density (MVD) status by immunohistochemistry: Small-interfering RNA ( siRNA) was used to determine the impact of altered Sp1 expression on tumor growth and angiogenesis, and mithramycin A (MIT) was used to evaluate Sp1-targeted antiangiogenic treatment of human pancreatic cancer in animal models. RESULTS: CONCLUSIONS: Both clinical and experimental evidence indicated that Sp1 is a critical regulator of human pancreatic cancer angiogenesis and the antitumor activity of MIT is a result, at least in part, of the suppression of Sp1 expression and consequent down-regulation the downstream targets of Sp1 that are key to angiogenesis.
|
Authors | Ping Yuan, Liwei Wang, Daoyan Wei, Jun Zhang, Zhiliang Jia, Qiang Li, Xiangdong Le, Huamin Wang, James Yao, Keping Xie |
Journal | Cancer
(Cancer)
Vol. 110
Issue 12
Pg. 2682-90
(Dec 15 2007)
ISSN: 0008-543X [Print] United States |
PMID | 17973266
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | 2007 American Cancer Society |
Chemical References |
- Angiogenesis Inhibitors
- RNA, Small Interfering
- Sp1 Transcription Factor
- mithramycin A
- Plicamycin
|
Topics |
- Adenocarcinoma
(blood supply, drug therapy, metabolism)
- Angiogenesis Inhibitors
(pharmacology, therapeutic use)
- Animals
- Cell Line, Tumor
- Female
- Humans
- Mice
- Mice, Inbred C57BL
- Mice, Nude
- Pancreatic Neoplasms
(blood supply, drug therapy, metabolism)
- Plicamycin
(analogs & derivatives, pharmacology, therapeutic use)
- RNA, Small Interfering
(pharmacology)
- Sp1 Transcription Factor
(antagonists & inhibitors, physiology)
- Xenograft Model Antitumor Assays
|